Br J HaematolL:预防性治疗能降低严重血友病甲或乙患儿的脑出血风险

2017-07-14 xiaoxiao MedSci原创

血友病,是一组由于血液中某些凝血因子的缺乏而导致患者产生严重凝血障碍的遗传性出血性疾病,男女均可发病,但绝大部分患者为男性。血友病在先天性出血性疾病中最为常见,出血是该病的主要临床表现。该病的出血大多为创伤后出血,只是有时创伤极轻微而未被注意,因而似乎是“自发”出血。出血部位常在较深的组织,包括关节、肌肉、脑、腹膜后血肿,出血部位肿胀及疼痛是主要的症状。

血友病,是一组由于血液中某些凝血因子的缺乏而导致患者产生严重凝血障碍的遗传性出血性疾病,男女均可发病,但绝大部分患者为男性。血友病在先天性出血性疾病中最为常见,出血是该病的主要临床表现。该病的出血大多为创伤后出血,只是有时创伤极轻微而未被注意,因而似乎是“自发”出血。出血部位常在较深的组织,包括关节、肌肉、脑、腹膜后血肿,出血部位肿胀及疼痛是主要的症状。

血友病包括血友病甲(凝血因子VIII缺乏)、血友病乙(凝血因子IX缺乏)、和因子XI缺乏症(曾称血友病丙)三型。我国血友病研究协作组数据显示血友病患者中甲:乙:丙三型比为28:5:1。血友病目前还没有根治的办法。迄今,血友病最有效的治疗方法是替代治疗,即补充凝血因子。


目前医学界对血友病的预防性治疗多集中在联合治疗。预防性治疗对颅内出血的影响还不太清楚。7月发表在Br J Haematol上的一篇研究对血友病患儿脑出血的发生情况,及不同的预防方案和脑出血后遗症进行了探讨。

这是一项多中心回顾性和前瞻性研究,研究共纳入了来自20个国家的33个血友病中心的患儿。纳入标准为1993年-2014年间出生的患有严重的血友病甲型或乙型患者。根据定期输注预防性治疗药物的剂量和剂量频率,研究人员把参与者按预防性治疗方案分类:完全预防组、部分预防组或未预防组。

本队列研究共包括1515名儿童:在超过8038病人-年中共报告了29例脑出血患者。完全预防组脑出血/病人-年的发生率为0.00033,明显低于无预防组患者(0.017;RR 50.06;p<0.001),而部分预防组脑出血/病人-年的发生率为0.0050(RR 14.92,p=0.007)。在预防性治疗的两组中,8%(2/24)的患儿发生脑出血死亡,33%的患儿存在长期后遗症(包括智力问题、行为问题、轻度瘫痪和癫痫)。

研究结果表明,与不频繁甚至不使用预防药物的血友病患者相比,定期、频繁使用预防药物的患者脑出血的危险性较低。

原始出处:

Andersson NG, Auerswald G,et al.Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14844. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993014, encodeId=c0501993014ec, content=<a href='/topic/show?id=f5ca1003182f' target=_blank style='color:#2F92EE;'>#预防性治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100318, encryptionId=f5ca1003182f, topicName=预防性治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 08:58:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008282, encodeId=5ddf20082829a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Jan 26 13:58:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034773, encodeId=d40c2034e7371, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Nov 15 16:58:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317322, encodeId=7674131e3222b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jul 16 14:58:00 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993014, encodeId=c0501993014ec, content=<a href='/topic/show?id=f5ca1003182f' target=_blank style='color:#2F92EE;'>#预防性治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100318, encryptionId=f5ca1003182f, topicName=预防性治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 08:58:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008282, encodeId=5ddf20082829a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Jan 26 13:58:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034773, encodeId=d40c2034e7371, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Nov 15 16:58:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317322, encodeId=7674131e3222b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jul 16 14:58:00 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
    2018-01-26 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1993014, encodeId=c0501993014ec, content=<a href='/topic/show?id=f5ca1003182f' target=_blank style='color:#2F92EE;'>#预防性治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100318, encryptionId=f5ca1003182f, topicName=预防性治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 08:58:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008282, encodeId=5ddf20082829a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Jan 26 13:58:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034773, encodeId=d40c2034e7371, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Nov 15 16:58:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317322, encodeId=7674131e3222b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jul 16 14:58:00 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1993014, encodeId=c0501993014ec, content=<a href='/topic/show?id=f5ca1003182f' target=_blank style='color:#2F92EE;'>#预防性治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100318, encryptionId=f5ca1003182f, topicName=预防性治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Mon Jun 11 08:58:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008282, encodeId=5ddf20082829a, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Fri Jan 26 13:58:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034773, encodeId=d40c2034e7371, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Nov 15 16:58:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317322, encodeId=7674131e3222b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Jul 16 14:58:00 CST 2017, time=2017-07-16, status=1, ipAttribution=)]
    2017-07-16 fengyi812

相关资讯

加拿大报道:一种血友病治疗新方案

一项包括几位加拿大患者的小规模基因疗法试验,为血友病患者提供了新的希望。血友病是一种致命的遗传性罕见病。由于缺乏凝血因子或蛋白质,血友病患者会遭受长期无法控制的出血,甚至轻微创伤就会出血。血友病有两种类型,A 型和 B 型,这两种都是非常罕见的疾病。根据加拿大血友病学会(的数据),A 型血友病在加拿大约有 2500 名患者,而 B 型血友病在加拿大约有 600 名患者。费城儿童医院开发的一种新基因

INT J LAB HEMATOL:中国南方A型血友病的遗传诊断:五个新突变和一个植入前遗传分析

由于目前尚未完全治愈A型血友病(HA),因此鉴定HA患者和携带者的VIII(FVIII)基因的病原性突变,将有助于产前诊断遗传咨询和植入前遗传诊断(PGD),也是是防治A型血友病的重要措施。

重磅:基因编辑再创奇迹,有望根治血友病, 人类如何打开潘多拉之盒?

6月27日,媒体报道日本研究人员利用基因编辑技术成功治疗了小鼠血友病,未来有望根治人类的遗传性血友病。

SCI REP:基因编辑技术成功治疗实验鼠血友病

日本一个研究小组近日表示,他们利用基因编辑技术成功治疗了实验鼠的血友病。未来有望在此基础上开发出能根治血友病的疗法。

Blood:定期更换凝血因子显著帮助减少血友病关节出血发生

这项研究证明了采取预防性措施定期更换凝血因子对于预防血友病关节出血事件发生有明显的帮助。为执行这一措施和疗法提供了数据依据和支持。

专题: 改善生命质量,携手对抗罕见病十周年:2.28国际罕见病指南合集[合集]

每年2月的最后一天是国际罕见病日,2017年的国际罕见病主题是“研究”,今年罕见病日的主题是“研究带来无限可能”。罕见病属于发病率极低、很少见的疾病。约有80%的罕见病是由遗传缺陷所致,其中一半的罕见病患者在出生时或者儿童期即可发病,病情常常进展迅速,通常会危及生命。对于罕见病的诊疗,我国尚处于起步阶段,大家对罕见病的认知不够、预防意识有待加强,有一步部分医务人员对罕见病缺乏诊断治疗经验和研究,误